Evidence map›Paper›PMID 34433909›Full record

ArticleOncogene2021

Comprehensive molecular profiling of UV-induced metastatic melanoma in Nme1/Nme2-deficient mice reveals novel markers of survival in human patients.

M Kathryn Leonard, Gemma S Puts, Nidhi Pamidimukkala, Gautam Adhikary, Yili Xu, Eric Kwok, Yuxin Jin, Devin Snyder, Nicolette Matsangos, Marián Novak and 15 more

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The mCell death discovery · 2024
    Article
  5. Review
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 1 country.

M Kathryn LeonardDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-8432-6803
Gemma S PutsDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.
Nidhi PamidimukkalaDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.
Gautam AdhikaryDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.
Yili XuDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-8508-4706
Eric KwokDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Yuxin JinDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Devin SnyderDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-8528-7538
Nicolette MatsangosDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-3542-2612
Marián NovakDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.
Anup MahurkarInstitute for Genome Sciences, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-4999-2296
Amol C ShettyInstitute for Genome Sciences, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.ORCID http://orcid.org/0000-0001-8790-7649
Radomir M SlominskiDepartment of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Edward C De FaboThe George Washington University Medical Center, Washington, DC, USA.
Frances P NoonanThe George Washington University Medical Center, Washington, DC, USA.ORCID http://orcid.org/0000-0002-3302-7280
Chi-Ping DayLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-5200-2372
Mohammed RigiDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Andrzej T SlominskiDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Michelle G WebbDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-7613-5759
David W CraigDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-2040-1955
Glenn MerlinoLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Richard L EckertDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA.
John D CarptenDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Zarko ManojlovicDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-9705-4088
David M KaetzelDepartment of Biochemistry and Molecular Biology, School of Medicine, University of Maryland-Baltimore, Baltimore, MD, USA. DKaetzel@som.umaryland.edu.ORCID http://orcid.org/0000-0003-2761-8970
University of Maryland, Baltimore · USUniversity of Southern California · USUniversity of Alabama at Birmingham · USGeorge Washington University · USNational Cancer Institute · US

Funding

UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9M
Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
Mechanism of action and function of novel secosteroid 20(OH)D3 in the skinR01AR073004 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ANDRZEJ T SLOMINSKI · 2018 to 2026
$2.9M
Suppression of Melanoma Initiation and Progression by NM23-H1R01CA159871 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI KAETZEL, DAVID M · 2012 to 2016
$2.2M
A novel sulforaphane cancer preventionmechanismR01CA211909 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI ECKERT, RICHARD L. · 2018 to 2022
$2.1M
NM23 PROTEINS AND MECHANISMS OF PDGF A CHAIN SILENCINGR01CA083237 · NCI · UNIVERSITY OF KENTUCKY · PI KAETZEL, DAVID M · 1999 to 2010
$1.9M
Significance of metabolic activation of lumisterol in the skinR01AR071189 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SLOMINSKI, ANDRZEJ T · 2017 to 2021
$1.6M
CYP11A1-derived secosteroids as therapeutic agents in UVB induced skin cancerI01BX004293 · VA · BIRMINGHAM VA MEDICAL CENTER · PI SLOMINSKI, ANDRZEJ T · 2019 to 2025
–
BLRD VA I01 BX004293NCI NIH HHS P30 CA134274NCI NIH HHS R01 CA083237NCI NIH HHS R01 CA159871NCI NIH HHS R01 CA211909NCI NIH HHS T32 CA154274NIAMS NIH HHS R01 AR071189NIAMS NIH HHS R01 AR073004NIGMS NIH HHS R25 GM055036
6 · The paper itself

Abstract

Hepatocyte growth factor-overexpressing mice that harbor a deletion of the Ink4a/p16 locus (HP mice) form melanomas with low metastatic potential in response to UV irradiation. Here we report that these tumors become highly metastatic following hemizygous deletion of the Nme1 and Nme2 metastasis suppressor genes (HPN mice). Whole-genome sequencing of melanomas from HPN mice revealed a striking increase in lung metastatic activity that is associated with missense mutations in eight signature genes (Arhgap35, Atp8b4, Brca1, Ift172, Kif21b, Nckap5, Pcdha2, and Zfp869). RNA-seq analysis of transcriptomes from HP and HPN primary melanomas identified a 32-gene signature (HPN lung metastasis signature) for which decreased expression is strongly associated with lung metastatic potential. Analysis of transcriptome data from The Cancer Genome Atlas revealed expression profiles of these genes that predict improved survival of patients with cutaneous or uveal melanoma. Silencing of three representative HPN lung metastasis signature genes (ARRDC3, NYNRIN, RND3) in human melanoma cells resulted in increased invasive activity, consistent with roles for these genes as mediators of the metastasis suppressor function of NME1 and NME2. In conclusion, our studies have identified a family of genes that mediate suppression of melanoma lung metastasis, and which may serve as prognostic markers and/or therapeutic targets for clinical management of metastatic melanoma.

Indexed as

AnimalsBiomarkers, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHepatocyte Growth FactorHumansLung NeoplasmsMelanomaMiceMutation, MissenseNM23 Nucleoside Diphosphate KinasesSequence Analysis, RNASurvival AnalysisUltraviolet RaysWhole Genome SequencingBiomarkers, TumorHepatocyte Growth FactorHGF protein, mouseNM23 Nucleoside Diphosphate KinasesNme1 protein, mouseNme2 protein, mouse

Identifiers

PMID34433909
PMCPMC8595820
OpenAlexW3193880119

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.